- BNF:
- Not listed
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- August 2017
Comments
RED:
- NICE TA573: daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma. (Decision date - May 2019).
- NICE TA763: daratumumab in combination for untreated multiple myeloma
when a stem cell transplant is suitable. (Decision date - March 2022).
- NICE TA783: daratumumab monotherapy for treating relapsed and refractory multiple myeloma. (Replaces NICE TA510). (Decision date - May 2022).
- NICE TA897 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma. (Decision date - July 2023)
- NICE TA917 - Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable. NHSE commissioned. (Decision date - November 2023)
- NICE TA634 - (Updated from DNP) Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma. NICE TA634 terminated appraisal (Decision date - November 2023)
DO NOT PRESCRIBE (DNP):
- NICE TA454: daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. (Terminated appraisal). (Decision date - August 2017)
- NICE TA726: Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. (Terminated appraisal). (Decision date - Oct 2021).
- NICE TA771: Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma. (Terminated appraisal). (Decision date - March 2022).
NHS England drug. To be used in line with NHS England commissioning intentions.
Do Not Prescribe (DNP) Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again
